GlassScriptPhysician profile
Waddah Allaf
NPI 1386607836
$6,551.35
in general payments reported to CMS, 2019-2025
22 companies · $1,018 in 2025
The $1,018 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $904 · 2020: $772 · 2021: $1,007 · 2022: $675 · 2023: $1,304 · 2024: $872 · 2025: $1,018.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,193.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,193.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,386.94 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Astrazeneca Pharmaceuticals LP | $1,335.61 | 2019-2025 | Airsupra, Breztri, Fasenra |
| Ani Pharmaceuticals, INC. | $585.37 | 2023-2025 | Purified Cortrophin Gel |
| Mallinckrodt Hospital Products INC. | $560.00 | 2020-2023 | Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $290.05 | 2019-2025 | Ofev, Jascayd, Spiriva |
| Mallinckrodt Enterprises LLC | $214.63 | 2019 | |
| Verona Pharma, INC. | $202.98 | 2025 | Ohtuvayre |
| Mylan Specialty L.P. | $174.73 | 2022-2024 | Yupelri |
| Genzyme Corporation | $164.61 | 2024-2025 | |
| Inari Medical, INC. | $125.49 | 2021 | |
| Insmed, INC. | $124.99 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $108.79 | 2022 | |
| United Therapeutics Corporation | $44.23 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $43.61 | 2025 | Dupixent |
| Baxter Healthcare | $39.59 | 2022-2025 | Hillrom - Vest System Model 105 Home Care |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Circassia INC. | $33.85 | 2019-2020 | |
| Viatris Specialty LLC | $29.47 | 2025 | Yupelri |
| Inogen, INC. | $26.67 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Amgen INC. | $21.52 | 2021 | |
| Nabriva Therapeutics, Plc | $19.36 | 2020 | |
| Merck Sharp & Dohme LLC | $18.86 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Waddah Allaf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.